13,14-DIHYDRO-15-KETO PROSTAGLANDIN E2

Description

13,14-dihydro-15-keto Prostaglandin E₂ (13,14-dihydro-15-keto PGE₂) is a metabolite of PGE₂ and the primary PGE₂ metabolite in plasma. It is formed from PGE₂ via a 15-keto PGE₂ intermediate by 15-oxo-PG Δ¹³ reductase. Unlike PGE₂, 13,14-dihydro-15-keto PGE₂ does not bind effectively to the PGE₂ receptors EP₂ and EP₄ expressed in CHO cells (K_is = 12 and 57 μM, respectively) or induce adenylate cyclase activity in the same cells (EC₅₀s = >18 and >38 μM, respectively). Levels of 13,14-dihydro-15-keto PGE₂ are increased in the plasma of women in the third trimester of pregnancy and in women during and immediately after labor and delivery. Levels of 13,14-dihydro-15-keto PGE₂ levels are decreased in tumor tissue compared to adjacent non-cancerous tissue isolated from patients with non-small cell lung cancer (NSCLC).

Uses

13,14-Dihydro-15-ketoPGE2 is a primary metabolite of PGE2 in plasma.

Definition

ChEBI: The 13,14-dihydro derivative of 15-oxo-prostaglandin E2.